Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. Lumos Pharma
LUMO

Buy Lumos Pharma (LUMO) Stock

LUMO
See LUMO stock price and Buy/Sell Lumos Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
LUMO

Lumos Pharma (LUMO)

About Lumos Pharma (LUMO)

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Market Cap
$74.98M
1 Year High
$10.57
Volume
5.97k
1 Year Low
$6.15
Price to Earnings Ratio
Open
$8.88
Dividend Rate
High
$9.27
Dividend Yield
Low
$8.70

Community

People who own or watch LUMO stock

Lumos Pharma Price Targets

What analysts think LUMO stock price will be.
$8.82
$23.71
168.8% Upside
$5$25

Lumos Pharma Stock Rating

What analysts recommend for LUMO stock, on a scale from 1(buy) to 5(sell).
Strong Buy1 / 5
BuyHoldSell

Lumos Pharma Stock Earnings

The value each LUMO share was expected to gain vs. the value that each LUMO share actually gained.
Expected
Actual

Lumos Pharma Stock News

Frequently Asked Questions (FAQ)

As of Sep 28, 2022, the market cap for LUMO stock is $74.98M

The 52-week high for LUMO stock is $10.57. The current LUMO stock price $8.82 is 16.56% below its 52-week high

The 52-week low for LUMO stock is $6.15. The current LUMO stock price $8.82 has increased 30.27% from its 52-week low

No, the LUMO stock does not pay dividends to its shareholders

The target price for LUMO stock is $23.71 based on the average of what a group of analyst think LUMO stock could be worth at a future date. This is not a prediction by Public.com

Buy Lumos Pharma (LUMO) Stock

LUMO
See LUMO stock price and Buy/Sell Lumos Pharma with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch LUMO stock
  • Rmartinez92 avatar
  • raregem63 avatar
  • bush1564 avatar
  • elchrichri avatar
  • junset avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.